InSilico Medicine (InSilico) is an artificial intelligence-driven pharma-technology company that focuses on accelerating drug discovery and development.
It provides integrated drug discovery software suite products including PandaOmics, multi-omics target discovery and deep biology analysis engine to discover novel targets. The company offers Chemistry 42, a machine learning de-novo drug design engineering platform to generate novel molecules; and Inclinico, to design and predict clinical trials.
InSilico works in collaboration with pharmaceutical companies to develop drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s disease, Alzheimer’s disease, diabetes, sarcopenia, aging and others.
It operates in Hong Kong and the US. InSilico is headquartered in Hong Kong.